

Rheumatology Referral Form

1. Patient Information

Patient Name: Birthdate: Sex: ☐ Male ☐ Female Weight: ☐ lbs. ☐ kg
 Preferred Phone: Known Allergies
 Address: City: State Zip:

****Insurance Information: Please fax FRONT and BACK copy of ALL Insurance cards (Prescription and Medical) ****

2. Prescriber Information

Prescriber Name: NPI# Tax ID#
 Address: Phone: Fax:
 City, State, Zip: Key Contact:

3. Diagnosis/Clinical Information

Diagnosis: ICD-10
 Prior Failed Medications: (medication and duration of treatment/reason for d/c)
☐ NSAID ☐ COX-2 ☐ sulfasalazine ☐ cyclosporine
☐ corticosteroids ☐ leflunomide ☐ methotrexate ☐ hydroxychloroquine
☐ Other DMARD: ☐ JAK Inhibitor ☐ TNF Inhibitor
☐ Other Biologic:
 Dates Used _____
 Reason for D/C:
 Is the Patient currently receiving other immunosuppressive therapy?
☐ Yes:
☐ No
 Other notes:
 Quantiferon TB Status: ☐ Positive ☐ Negative ☐ Pending

****Please FAX recent clinical notes, labs, and tests with the prescription to expedite the Prior Authorization****

4. Prescription Information

Medication	Dose/Strength	Sig	QTY.	Refills
☐ Actemra®	☐ 162/0.9 ml PFS	☐ Inject 162 mg SC every OTHER week ☐ Inject 162 mg SC ONCE a week	___ Week Supply	_____
☐ Benlysta®	☐ 200 mg/1ml autoinjector ☐ 200 mg/1ml PFS	☐ Inject 200 mg SC ONCE weekly	___ Week Supply	_____
☐ Bimzelx®	☐ 160 mg/1ml prefilled autoinjector ☐ 160 mg/1ml PFS ☐ 320 mg/2ml prefilled autoinjector ☐ 320 mg/2ml PFS	☐ Inject 160 mg SC every 4 weeks ☐ Inject 320 mg SC _____	___ Week Supply	_____
☐ Cimzia®	☐ 200 mg/1ml PFS	☐ Starter Dose: Inject 400 mg SC at weeks 0, 2, and 4 ☐ Maintenance Dose: Inject 2 PFS SQ every 4 weeks or Inject 1 PFS every 2 weeks	___ Week Supply	_____
☐ Cosentyx®	☐ 150 mg/1ml Sensoready pen ☐ 150 mg/1ml PFS ☐ 300 mg/2ml UnoReady pen 300 mg/2ml PFS	☐ Starter Dose: 150 mg SC at weeks 0, 1, 2, 3, and 4 ☐ Maintenance Dose: Inject 150 mg SC every 4 weeks ☐ Starter Dose: 300 mg SC at weeks 0, 1, 2, 3, and 4 ☐ Maintenance Dose: Inject 300 mg SC every 4 weeks Other Dose Schedule: _____	___ Week Supply	_____
☐ Enbrel®	☐ 50 mg/1ml PFS ☐ 50 mg/1ml SureClick™ autoinjector ☐ 50 mg/1ml Mini™ With AutoTouch™ ☐ 25 mg/0.5ml PFS	☐ Inject 50 mg SC ONCE a week ☐ Other: _____	___ Week Supply	_____
☐ Folic acid	☐ 400 mcg ☐ 800 mcg ☐ 1 mg	☐ Take _____tablets by mouth daily	___ Week Supply	_____
☐ Humira®	☐ 40 mg/0.4ml Citrate Free PFS ☐ 40 mg/0.4ml Citrate Free Pen	☐ Inject 40 mg SC every OTHER week ☐ Inject 40 mg SC ONCE a week ☐ Other: _____	___ Week Supply	_____
☐ Ilumya®	☐ 100 mg/1ml PFS	☐ Inject 100 mg SC at weeks 0,4, and every 12 weeks thereafter	___ Week Supply	_____
☐ Kevzara®	☐ 150 mg/1.14ml PFS ☐ 200 mg/1.14ml PFS ☐ 150 mg/1.14ml Pen ☐ 200 mg/1.14ml Pen	☐ Inject 200 mg SC once every 2 weeks ☐ Other: _____	___ Week Supply	_____
☐ Methotrexate	☐ 2.5 mg	☐ Take _____tablets by mouth weekly	___ Week Supply	_____

Rheumatology Referral Form

Medication	Dose/Strength	Sig	QTY.	Refills
☐ Olumiant®	☐ 2 mg tablets ☐ 1 mg tablets	☐ Take 1 tablet ONCE daily	___ Week Supply	___
☐ Orenzia®	☐ 125 mg/mL ClickJect™ ☐ 125 mg/mL PFS	☐ Inject 125 mg SC once weekly	___ Week Supply	___
☐ Otezla®	☐ Starter Pack ☐ 30 mg tablets	☐ Starter Dose: 28 Days as directed (follow package directions) ☐ Maintenance Dose: Take 1 tablet twice daily	___ Week Supply	___
☐ Otrexup®	☐ 10 mg/0.4 mL ☐ 12.5 mg/0.4 mL ☐ 15 mg/0.4 mL ☐ 17.5 mg/0.4 mL	☐ 20 mg/0.4 mL ☐ 22.5 mg/0.4 mL ☐ 25 mg/0.4 mL ☐ Inject _____ SC once weekly	___ Week Supply	___
☐ Rasuvo®	☐ 7.5 mg/0.15mL ☐ 10 mg/0.2mL ☐ 12.5 mg/0.25mL ☐ 15 mg/0.30mL ☐ 17.5 mg/0.35mL	☐ 20 mg/0.4mL ☐ 22.5 mg/0.45mL ☐ 25 mg/0.5mL ☐ 27.5 mg/0.55mL ☐ 30 mg/0.6mL ☐ Inject _____ SC once weekly	___ Week Supply	___
☐ Rayos®	☐ 1 mg delayed-release tablets ☐ 2 mg Delayed-release tablets ☐ 5 mg Delayed-release tablets	☐ Take ___ tablets ___ times per day by mouth with food	___ Week Supply	___
☐ Rinvoq®	☐ 15 mg tablets	☐ Take 1 tablet by mouth daily	___ Week Supply	___
☐ Simponi®	☐ 50 mg PFS ☐ 50 mg SmartJect® ☐ 100 mg SmartJect® ☐ 100 mg PFS	☐ Inject 50 mg SC every 4 weeks ☐ Other: _____	___ Week Supply	___
☐ Skyrizi®	☐ 150 mg/1ml single dose prefilled pen ☐ 150 mg/1ml PFS	☐ Inject 150 mg SC at week 0, week 4, and every 12 weeks thereafter	___ Week Supply	___
☐ Stelara®	☐ 45 mg/0.5ml PFS ☐ 90 mg/1ml PFS	☐ Starter Dose: Inject _____ SC weeks 0 and 4 ☐ Maintenance Dose: Inject _____ SC every 12 weeks	___ Week Supply	___
☐ Taltz®	☐ 80 mg/mL single-dose prefilled Autoinjector ☐ 80 mg/mL single-dose PFS	☐ Starter Dose: Inject 160 mg SC at week 0; _____ ☐ Maintenance Dose: 80mg SQ _____ ☐ Other Dose Schedule: _____	___ Week Supply	___
☐ Tremfya®	☐ 100 mg/1ml One-Press Patient controlled injector ☐ 100 mg/1ml prefilled pen ☐ 100 mg/1ml PFS	☐ Inject 100 mg by SC at week 0, week 4, and every 8 weeks thereafter	___ Week Supply	___
☐ Xeljanz®	☐ 5 mg tablets ☐ 11mg XR tablets	☐ Take 1 tablet by mouth TWICE daily ☐ Take 1 tablet by mouth daily	___ Week Supply	___
☐ Other:			___ Week Supply	___

Dispensing Options: ☐ Pick-Up | Deliver To: ☐ Patient's Home ☐ Prescriber's Office

Prescriber Signature: Prescriber, please sign and date below

Date

I authorize Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the intended recipient, do not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.